Impact of Subsequent Immune Checkpoint Inhibitor Treatment on Overall Survival With Avelumab vs Docetaxel in Platinum-Treated Advanced NSCLC: Post Hoc Analyses From the Phase 3 JAVELIN Lung 200 Trial

Avelumab is a human anti –programmed cell death 1 ligand 1 (PD-L1) IgG1 antibody that has shown durable antitumor activity and an acceptable safety profile in patients with a range of tumor types [1–7]. Avelumab has been approved as monotherapy for the treatment of Merkel cell carcinoma and for urothelial carcinoma that has not progressed (first-line maintenance therapy) or progressed (second-line therapy) with platinum-containing chemotherapy, as well as in combination with axitinib as first-line treatment for renal cell carcinoma [8,9].

Source: Lung Cancer - February 5, 2021 Category: Cancer & Oncology Authors: Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David Spigel, James C.-H. Yang, Marcis Bajars, Mary Ruisi, Juliane Manitz, Fabrice Barlesi Source Type: research